Precirix Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Employees
  • 36

Employees

  • Latest Deal Type
  • Liquidation

Precirix General Information

Description

Developer of radio-immunotherapeutic drugs designed to offer a new generation of targeted cancer therapies. The company's drugs are based on the camelid immune system, which uses antigen-binding fragments to transport therapeutic radioisotopes to selected target receptors on the cancer cell surface, enabling patients to receive personalized cancer medicine.

Contact Information

Website
www.precirix.com
Formerly Known As
Camel-IDS
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Burgemeester Etienne Demunterlaan 1b
  • 3 Jette
  • 1090 Brussels
  • Belgium
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Burgemeester Etienne Demunterlaan 1b
  • 3 Jette
  • 1090 Brussels
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Precirix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Bankruptcy: Liquidation 20-Jan-2026 Completed Bankruptcy: Liquidation
9. Later Stage VC (Series B) 16-Mar-2022 Completed Clinical Trials - Phase 2
8. Grant 01-Jan-2019 Completed Clinical Trials - Phase 1
7. Early Stage VC (Series A) 16-Nov-2018 Completed Clinical Trials - Phase 1
6. Early Stage VC 24-Oct-2017 Completed Startup
5. Grant 01-Dec-2015 Completed Startup
4. Grant 01-Dec-2014 Completed Startup
3. Capitalization 01-Oct-2014 Completed Startup
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2014 Completed Startup
To view Precirix’s complete valuation and funding history, request access »

Precirix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference B Shares
Preference A Shares
Ordinary 15,000 $110.83 $110.83 1x $110.83 5.11%
To view Precirix’s complete cap table history, request access »

Precirix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of radio-immunotherapeutic drugs designed to offer a new generation of targeted cancer therapies. The company'
Discovery Tools (Healthcare)
Brussels, Belgium
36 As of 2025

Pasadena, CA
 

Columbus, OH
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Precirix Competitors (24)

One of Precirix’s 24 competitors is Meditope Biosciences, a Formerly VC-backed company based in Pasadena, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Meditope Biosciences Formerly VC-backed Pasadena, CA
Navidea Biopharmaceuticals Corporate Backed or Acquired Columbus, OH
Genprex Formerly VC-backed Austin, TX
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 24 competitors. Get the full list »

Precirix Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 15

    Pending

  • Expiring in next 12 mo

Precirix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023264245-A1 Pre-targeting Pending 02-May-2022
EP-4518911-A1 Pre-targeting Pending 02-May-2022
US-20250122304-A1 Pre-targeting Pending 02-May-2022
WO-2023213801-A1 Pre-targeting Inactive 02-May-2022
WO-2023203135-A1 Improved radiolabelled antibody Inactive 22-Apr-2022 A61P35/00
To view Precirix’s complete patent history, request access »

Precirix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Precirix FAQs

  • When was Precirix founded?

    Precirix was founded in 2014.

  • Where is Precirix headquartered?

    Precirix is headquartered in Brussels, Belgium.

  • What is the size of Precirix?

    Precirix has 36 total employees.

  • What industry is Precirix in?

    Precirix’s primary industry is Discovery Tools (Healthcare).

  • Is Precirix a private or public company?

    Precirix is a Private company.

  • What is Precirix’s current revenue?

    The current revenue for Precirix is .

  • How much funding has Precirix raised over time?

    Precirix has raised $133M.

  • Who are Precirix’s competitors?

    Meditope Biosciences, Navidea Biopharmaceuticals, Genprex, Light Chain Bioscience, and Kite Pharma are some of the 24 competitors of Precirix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process